Novigenix SA

Meet the Novigenix SA team at #ESMO2024 to learn about Next Generation Immune Intelligence with predictive capabilities powered by AI-enabled RNA analytics. If you're attending, don’t miss our poster on a novel multimodal approach to predict response to immune checkpoint inhibitors in metastatic urothelial cancer: 📍 Location: ESMO 2024, urothelial cancer section, poster 2000P 🗓️ Date: Sunday, September 15th, from 12:00-13:30 Feel free to reach out to our CEO Dr. Brian Hashemi, Chief Medical & Scientific Officer Dr. Pedro Romero or Senior Scientist Dr. Amaia Martinez Usatorre to explore potential collaboration opportunities! For more details: https://lnkd.in/dTjmMd_T #PrecisionMedicine #AI #ImmuneProfiling #CancerResearch #Innovation #Biopharma #Oncology #Immunotherapy #Immunotranscriptomic #UrothelialCancer

Meet the Novigenix SA team at #ESMO2024 to learn about Next Generation Immune Intelligence with predictive capabilities powered by AI-enabled RNA analytics. If you're attending, don’t miss our poster on a novel multimodal approach to predict response to immune checkpoint inhibitors in metastatic urothelial cancer: 📍 Location: ESMO 2024, urothelial cancer section, poster 2000P 🗓️ Date: Sunday, September 15th, from 12:00-13:30 Feel free to reach out to our CEO Dr. Brian Hashemi, Chief Medical & Scientific Officer Dr. Pedro Romero or Senior Scientist Dr. Amaia Martinez Usatorre to explore potential collaboration opportunities! For more details: https://lnkd.in/dTjmMd_T #PrecisionMedicine #AI #ImmuneProfiling #CancerResearch #Innovation #Biopharma #Oncology #Immunotherapy #Immunotranscriptomic #UrothelialCancer

We are thrilled that Novigenix SA has successfully achieved ISO 13485:2016 certification from BSI, passing the Stage II audit with zero non-conformities. This significant milestone underscores Novigenix SA's unwavering commitment to the highest standards of quality in delivering cutting-edge solutions for the biopharma industry. Learn more here: https://lnkd.in/dyyuH-AS

Join us at the "Life Science Industry Meets Data Science" Symposium in Muttenz, where Noushin Hadadi, Novigenix SA's Director of Data Science & Bioinformatics, will be presenting on the transformative role of AI-powered RNA analytics in precision medicine. Our latest work at Novigenix SA focuses on enhancing the predictive power of RNA analytics to illuminate the immune landscape of each patient. This approach enables prediction of treatment response and drive groundbreaking drug development. Key highlights from Noushin Hadadi’s presentation include: - Harnessing AI to advance RNA analytics and predict treatment responses. - Immune Intelligence through advanced RNA profiling - Bridging the gap between data science and life sciences to revolutionize patient care If you're attending, don’t hesitate to reach out to Noushin Hadadi to explore potential synergies! 📍 Location: FHNW Muttenz (Basel area) 🗓️ Date: September 5, 2024 #AI #RNAAnalytics #PrecisionMedicine #LifeScience #Innovation #ImmuneIntelligence

Comprehensive LBx Transcriptomics offers deep insights into patient heterogeneity and immune response to disease progression and therapy intervention. The LITOSeek™ AI-enabled multiomics platform has demonstrated unprecedented predictive capabilities by combining LBx mRNA & cfDNA to obtain a complete picture of host response to tumor evolution. Thank you to the MATWIN Board for recognition of this platform as "The Best 2024 Technology in Oncology"! #rna #AI #PrecisionOncology

Following the 9th edition of MEET2WIN, the European Partnering Convention dedicated to the fight against cancer, Novigenix SA has been awarded the recognition of ‘Best 2024 Technology Innovation’ in oncology by the MATWIN Board.    Big thanks to the MATWIN Board members for this prestigious recognition.    Learn more here: https://lnkd.in/duQx46E3   - Rick Baehner, MD, Exact Sciences - Kenneth W. Hance, PhD, MPH, GSK - Paul Hughes, Amgen - Viia Valge-Archer, AstraZeneca - Samantha Brandler, PhD, MBA, Bristol Myers Squibb - Mark Pearson, Boehringer Ingelheim - Claire Bloomfield, insitro - Khatereh Ahmadi, Merck - Anna Kruczynski, Pierre Fabre Oncology - Valérie Méresse Naegelen, Roche - Laurent Debussche, Sanofi - Alexandra (Sasha) Huhalov, Takeda - Jean-Pierre Bizzari, EORTC - European Organisation for Research and Treatment of Cancer

Following the 9th edition of MEET2WIN, the European Partnering Convention dedicated to the fight against cancer, Novigenix SA has been awarded the recognition of ‘Best 2024 Technology Innovation’ in oncology by the MATWIN Board.    Big thanks to the MATWIN Board members for this prestigious recognition.    Learn more here: https://lnkd.in/duQx46E3   - Rick Baehner, MD, Exact Sciences - Kenneth W. Hance, PhD, MPH, GSK - Paul Hughes, Amgen - Viia Valge-Archer, AstraZeneca - Samantha Brandler, PhD, MBA, Bristol Myers Squibb - Mark Pearson, Boehringer Ingelheim - Claire Bloomfield, insitro - Khatereh Ahmadi, Merck - Anna Kruczynski, Pierre Fabre Oncology - Valérie Méresse Naegelen, Roche - Laurent Debussche, Sanofi - Alexandra (Sasha) Huhalov, Takeda - Jean-Pierre Bizzari, EORTC - European Organisation for Research and Treatment of Cancer

Join us at the Rolex Learning center - Epfl to hear Noushin Hadadi our Director of Data Science & Bioinformatics talk about AI in Precision Medicine. Looking forward to engaging discussion with thought leaders at Connect https://sdsc-connect.ch/ on how AI is positioned to accelerate precision medicine for better patient outcomes! #precisionmedicine #oncology #AI #Novigenix

Novigenix SA is the official immunotranscriptomic partner of the IMMUcan consortium, comprising academic, patient organization, and industry partners, under the leadership of Merck and EORTC - European Organisation for Research and Treatment of Cancer. By integrating our liquid biopsy LITOseek™ platform into the consortium, we intend to significantly enhance its immune profiling capabilities and ultimately propel the development of robust RNA biomarkers. These biomarkers will enhance patient stratification and monitoring during immunotherapy, and uncover previously unknown insights into patients undergoing immunotherapies.   In essence, the collaboration aims to bridge the gap between research and clinical application, bringing cutting-edge innovations to the forefront of cancer care and ultimately improving the lives of patients worldwide.    Read more here: https://lnkd.in/d5ndh4R4

Novigenix SA is thrilled to announce a pioneering partnership with IMMUcan, the largest immunotherapy consortium in Europe dedicated to reshaping cancer care! Through this partnership we are unlocking the power of liquid biopsy Immuno-Transcriptomics through AI analytics and RNA sequencing for personalized immunotherapy. Read more about this exciting development 👉 https://lnkd.in/dFG3Cuk7 #rna #AI #MultiOmics #PrecisionOncology #Immunotherapy